Arix Bioscience and BioMotiv Announce Strategic Partnership
CLEVELAND, OH, AND LONDON, U.K. – APRIL 18, 2016
Arix Bioscience, a global healthcare and life science company supporting medical innovation, and BioMotiv have formed a strategic investment partnership. Arix has committed $25 million to BioMotiv and has the opportunity to co-invest and further develop BioMotiv portfolio companies.
Arix was founded by leading figures in the international healthcare and life science sectors including Dr Joe Anderson, Chief Executive Officer, Jonathan Peacock, Chairman, and Professor Sir Christopher Evans, OBE, Deputy Chairman, and is backed by Woodford Investment Management and other institutional investors. BioMotiv and its companies will be able to leverage Arix’s renowned leadership team, extensive networks, and unique development platform.
Working together, Arix and BioMotiv will enable wide-ranging support for innovative university-sourced discoveries, accelerating them into novel medicines.